SCHEMBL2353154

SCHEMBL2353154

Cc1n[nH]c(=O)c(-c2ccccc2F)c1-c1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 3/20 0.44
LMNA P02545 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
CHEK1 O14757 1/20 0.39
AKT2 P31751 1/20 0.39
IKBKB O14920 1/20 0.38
MAP3K14 Q99558 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALPL P05186 1/20 0.38
NOTUM Q6P988 2/20 0.38
HSP90AA1 P07900 1/20 0.37
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
PTGS1 P23219 1/20 0.36
TNKS O95271 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36
HSD11B1 P28845 1/20 0.36
BRD4 O60885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2347368 0.90 CYP11B1 (0.39) APEX1LMNASMN1; SMN2CHEK1AKT2
SCHEMBL2351250 0.86 NPC1 (0.40) APEX1LMNASMN1; SMN2CHEK1AKT2
SCHEMBL2351989 0.86 PSD (0.40) IKBKBMAP3K14NOTUMGAAMAPT
SCHEMBL2347927 0.85 PSD (0.39) IKBKBMAP3K14ALPLNOTUMGAA
SCHEMBL2355006 0.84 KCNQ3 (0.42) LMNASMN1; SMN2IKBKBMAP3K14KDM4E
SCHEMBL2352712 0.83 PTGES (0.43) LMNASMN1; SMN2CHEK1AKT2IKBKB
SCHEMBL2351987 0.82 IKBKB (0.41) LMNASMN1; SMN2CHEK1AKT2IKBKB
SCHEMBL2350537 0.81 PSD (0.36) LMNASMN1; SMN2IKBKBMAP3K14KDM4E
SCHEMBL896357 0.81 DRD1 (0.40) IKBKBMAP3K14
SCHEMBL2350128 0.80 IKBKB (0.39) LMNASMN1; SMN2IKBKBMAP3K14KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008512-B2 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-30 US disclosed
US-8008512-B2 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-30 US disclosed
US-8008512-B2 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-30 US disclosed
US-20090281337-A1 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2009-11-12 US disclosed
US-20090281337-A1 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2009-11-12 US disclosed
US-20090281337-A1 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2009-11-12 US disclosed
US-7569518-B2 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-08-04 US disclosed
US-7569518-B2 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-08-04 US disclosed
US-7569518-B2 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-08-04 US disclosed
EP-1767529-B1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2009-05-06 EP disclosed
US-20080194566-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-08-14 US disclosed
US-20080194566-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-08-14 US disclosed
US-20080194566-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-08-14 US disclosed
EP-1767529-A1 PYRIDAZINE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2007-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194566-A1 Pyridazine Compound and Use Thereof PLPBP, PNPO, CYP4Z1 APEX1 3192/4885LMNA 3595/4885SMN1; SMN2 2919/4885
US-20090281337-A1 Pyridazine compound and use thereof PLPBP, PNPO, CYP4Z1 APEX1 3192/4885LMNA 3595/4885SMN1; SMN2 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.